drugset / Trial / NCT05153434
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
Phase 2
Completed
19 enrolled
Aardvark Therapeutics, Inc.
Children's Hospital Colorado · collabStanford University · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome
Timeline
- Start
- 2022-05-27
- Primary completion
- 2024-09-24
- Completion
- 2024-09-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARD-101 | Small molecule | 800 mg | Oral |